![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/01/2923225/20739/en/Ultragenyx-Reports-Second-Quarter-2024-Financial-Results-and-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/07/25/2919214/20739/en/Ultragenyx-to-Host-Conference-Call-for-Second-Quarter-2024-Financial-Results-and-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/07/24/2917948/20739/en/Ultragenyx-to-Present-GTX-102-Angelman-Syndrome-Program-Update-at-the-ASF-Family-Conference-and-Research-Symposium.html
https://www.globenewswire.com/news-release/2024/07/19/2916060/20739/en/Ultragenyx-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/07/17/2914885/20739/en/Ultragenyx-Announces-Successful-End-of-Phase-2-Meeting-with-FDA-for-GTX-102-Angelman-Syndrome-Program.html
https://www.fiercebiotech.com/biotech/ultragenyx-wins-surrogate-endpoint-debate-securing-green-light-seek-fda-approval-gene
https://www.fiercebiotech.com/biotech/ultragenyx-mereos-brittle-bone-drug-sustains-fracture-rate-cut-midphase-follow
https://www.globenewswire.com/news-release/2024/06/14/2898733/20739/en/Ultragenyx-Announces-Pricing-of-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html
https://www.globenewswire.com/news-release/2024/06/11/2897217/20739/en/Ultragenyx-and-Mereo-BioPharma-Announce-New-Phase-2-Data-from-Phase-2-3-Orbit-Study-Demonstrating-Sustained-Reductions-in-Fracture-Rates-Following-Treatment-with-Setrusumab-UX143-i.html